Hence, a reappraisal of metformin's impact on cardiovascular outcomes in comparison to that of GLP-1R agonists, DPP-4 inhibitors, and SGLT2 inhibitors should be taken into consideration with regards to how we manage people with T2DM. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.